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Abstract
Development of vaccines is essential for the prevention of future recurrences of severe acute respiratory
syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-
binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an
important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318–536)
RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and
protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded,
being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and
cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO
protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These
results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective
and safe SARS subunit vaccine.
Introduction
Anewly emerging infectious disease, severe acute re-spiratory syndrome (SARS), is caused by SARS cor-
onavirus (SARS-CoV) (27,46,58), a zoonotic virus that most
likely originated in its natural reservoir bats, through inter-
mediate transmission such as via palm civets and raccoon
dogs, and was finally transmitted to humans (21,37,38).
Transmission of SARS-CoV from humans to humans led to
the global outbreak of SARS in 2003 (39,44,45,52). Though
SARS is currently under control, it is necessary to develop
effective and safe vaccines for the prevention of future SARS
outbreaks that may arise from animal reservoirs or acciden-
tally due to laboratory virus escape.
Recently developed SARS vaccines are of various cate-
gories (18), including inactivated virus vaccines (49,51,59),
subunit vaccines (2,26), DNA vaccines (28,42,55), virus-like
particles (40,41), viral vector-based vaccines (4,19,34), and
different vaccine combinations (16,30,53). A variety of SARS
vaccines have been tested in animals, including monkeys,
ferrets, mice, and hamsters (1,7,9,20,33,48,49), and some of
them have been evaluated in humans (42). These vaccines
may target different antigens of the virus, but most of them
are based on the spike (S) protein. It has been reported that
an adenovirus-based vaccine expressing S protein prevented
pneumonia in ferrets after SARS-CoV challenge, and stimu-
lated potent immune responses in macaques (36). A recom-
binant SARS S-protein elicits neutralizing antibodies and
protection in mice (29). Specific humoral and cellular immune
responses and=or protection could be induced by SARS
S DNA vaccines via different vaccination routes (28,55). A
SARS-CoV-like particle carrying the S protein protected mice
from virus challenge (40). These reports suggest that the
S protein plays an important role in the prevention of SARS
infection (3).
Our previous studies demonstrated that a recombinant
fusion protein consisting of a 193-mer (residues 318–510)
receptor-binding domain (RBD) of SARS-CoV S protein
tagged with the Fc fragment of human IgG (RBD193-Fc)
could induce highly potent neutralizing antibody respon-
ses and protective immunity (14,25). However, one potential
disadvantage of this vaccine candidate is that the Fc tag,
which was added to the C-terminus of RBD193 in the hope of
increasing immunogenicity by binding Fc-tagged immunogen
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to the Fc receptor on antigen-presenting cells (5,47,57), may
cause adverse effects when used as a vaccine component in
humans. When we expressed a recombinant 193-mer RBD
(residues 318–510) without fusing Fc (RBD193-CHO) in
Chinese hamster ovary (CHO)-K1 cells, it induced RBD-
specific immune responses and neutralizing antibodies, but
could not fully protect vaccinated mice from SARS-CoV
challenge, with virus replication detected in two of five
vaccinated mice (15).
In the present study we expressed a 219-mer RBD protein
covering residues 318–539 in CHO-K1 cells (RBD219-CHO).
Like RBD193-Fc, this newly designed RBD without the Fc tag
(RBD219-CHO) can also induce strong humoral and cellular
immune responses, high titers of neutralizing antibodies, and
induces potent protective immunity that protected all vac-
cinated mice from SARS-CoV challenge. These results sug-
gest that RBD219-CHO has great potential for development
into an effective and safe SARS subunit vaccine.
Materials and Methods
Gene construction, protein expression,
and purification of RBD219-CHO
The gene construction and expression of RBD219-CHO
protein was done as previously described (15). The genes
encoding the fragment containing 219 aa (318–536) of the
SARS-CoV S protein RBD region, plus a 6His tag at the C
terminus, were amplified by PCR using a full-length S
plasmid (Tor2 strain) as the template (12, 24). It was then
inserted into the GS Gene Expression Vector PEE14.1. The
constructed recombinant plasmid (RBD219) was confirmed
by sequencing analysis. Briefly, the recombinant RBD219
plasmid was transiently transfected using FuGENE 6 trans-
fection reagents (Roche Applied Science, Indianapolis, IN)
into CHO-K1 cells precultured in F-12K medium (American
Type Culture Collection, Manassas, VA). The culture me-
dium was replaced by fresh OPTI-MEM I Reduced-Serum
Medium (Invitrogen, Carlsbad, CA) 10 h later, and the super-
natant was collected 72 h post-transfection. Culture super-
natant containing expressed protein was added to protease
inhibitor cocktails (Roche Applied Science) and purified using
His columns (Promega, Madison, WI). The protein yield us-
ing this transient transfection method was about 10.6 mg=L
supernatant.
Detection of RBD219-CHO protein reactivity
with RBD-specific mAbs
The reactivity of purified RBD219-CHO protein was
determined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), followed by Western blot, ac-
cording to our previously described protocols (10). Briefly,
purified protein (2mg=well) was separated by non-reducing
SDS-PAGE (no boiling and no reducing agent). The gel was
transferred to nitrocellulose membranes (Bio-Rad Labora-
tories, Hercules, CA), which were then blocked overnight at
48C with blocking buffer containing 5% non-fat milk dissolved
in 0.1% Tween 20-PBS (PBST). The blots were incubated for 1 h
at room temperature with serial RBD-specific monoclonal
antibodies (mAbs) generated in our laboratory (25), at a fi-
nal concentration of 0.5 mg=mL. After washing three times,
the blots were incubated with horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (1:5000; Zymed, Carlsbad,
CA) for 1 h at room temperature. Signals were visualized with
ECL Western blot Substrate Reagents and Amersham Hy-
perfilm (GE Healthcare, Piscataway, NJ).
Mouse vaccination and sample collection
A group of five female BALB=c mice 4–6 wk of age were
subcutaneously vaccinated with purified RBD219-CHO pro-
tein (20mg=mouse) in the presence of Freund’s complete ad-
juvant (FCA; Sigma, St. Louis, MO), and boosted twice with
the same immunogen (10 mg=mouse) containing Freund’s in-
complete adjuvant (FIA; Sigma) at 21-day intervals. Mice in-
jected with the same amount of PBS were used as negative
controls. Sera were collected pre-immunization and 10 d after
each vaccination, and analyzed for IgG and neutralizing an-
tibody responses. Spleen cells collected 10 d after the last
vaccination were used for the detection of cellular responses.
For parallel experiments, mice were challenged with SARS-
CoV 10 days after the last vaccination, and analyzed for viral
load and RNA copies in challenged lung tissues 5 d post-
challenge. Vaccination protocols are described in detail in Fig. 1.
Enzyme-linked immunosorbent assay (ELISA)
Mouse sera were analyzed using ELISA for IgG antibody
specific for RBD of SARS-CoV S protein using a previously
described protocol with some modifications (14). Briefly, 96-
well plates were pre-coated with 100mL=well of RBD219-CHO
protein (1 mg=mL) and sat overnight at 48C, then blocked with
2% non-fat milk at 378C for 2 h. Serially diluted mouse sera
were added to the plates at 100mL=well and incubated at 378C
for 1 h, followed by three washes with PBST. Bound antibodies
were then reacted with HRP-conjugated goat anti-mouse
IgG (1:2000) at 378C for 1 h. The substrate 3,30,5,50-
tetramethylbenzidine (TMB; Zymed) was added to the plates
FIG. 1. Vaccination protocol for the experiments.
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after three washes, followed by adding 1 N H2SO4 to stop the
reaction. The absorbance at 450 nm (A450) was measured by
an ELISA plate reader (Tecan Systems, San Jose, CA).
Neutralization assay for SARS pseudovirus infection
The neutralization assay against SARS-CoV pseudovirus
infection was done according to our previously established
method (25). Pseudotyped virus bearing SARS-CoV S pro-
tein, and defective HIV-1 genome expressing luciferase
as reporter was prepared as before. Briefly, 293T cells were
co-transfected with a plasmid encoding codon-optimized
SARS-CoV S protein, and a plasmid encoding Env-defective,
luciferase-expressing HIV-1 genome (pNL4-3.luc.RE), using
FuGENE 6 transfection reagents (Roche Applied Science).
Supernatants containing SARS pseudovirus were harvested
72 h post-transfection and used for single-cycle infection of
293T cells expressing ACE2 (ACE2=293T). The cells were
plated at 104 cells=well in 96-well tissue culture plates 24 h
pre-infection. The pseudovirus-containing supernatants were
pre-incubated with serially diluted mouse sera at 378C for 1 h
before they were added to the cells. After 24 h, the cells were
re-fed with fresh medium, which was followed by lysing the
cells 72 h later using cell lysis buffer (Promega), and the ly-
sates were transferred into 96-well luminometer plates. Lu-
ciferase substrate (Promega) was added to the plates, and
relative luciferase activity was determined with an Ultra 384
luminometer (Tecan Systems). The neutralization of SARS
pseudovirus was calculated (8), and presented as 50% neu-
tralizing antibody titer (NT50).
Neutralization assay for live SARS-CoV infection
Neutralization assay against the live SARS-CoV (GZ50
strain; GenBank accession no. AY304495) was done as pre-
viously described (16,17), and neutralizing antibody titers of
sera from mice immunized with RBD219-CHO protein were
detected in Vero E6 cells. Briefly, the cells were seeded (104=
well) on 96-well tissue culture plates 24 h before infection.
Serial twofold dilutions of serum samples were separately
mixed with 100 50% tissue-culture infectious dose (TCID50)
of the SARS-CoV GZ50 strain, incubated at 378C for 1 h, and
added to the cells in triplicate. Cytopathic effect (CPE) was
observed daily and recorded on day 3 post-infection. The
neutralizing titer was determined as the highest dilution of
sera that could completely prevent CPE in at least 50% of the
wells (NT50).
ELISPOT assay
ELISPOT assay was done using a mouse kit (Mabtech Inc.,
Mariemont, OH), according to the manufacturer’s protocol
and our previously described method (16,17). Briefly, 96-well
ELISPOT plates were coated with anti-IFN-g, anti-IL-2, and
anti-IL-4 mAbs overnight at 48C, and blocked with RPMI-
1640 containing 10% FBS for 2 h at room temperature. Single-
cell suspensions (2105 cells=well) isolated from vaccinated
mouse spleens were added to the wells, which was followed
by incubation at 378C for 24 h in the presence of an MHC-
H-2d-restricted SARS-CoV RBD-specific cytotoxic T lym-
phocyte (CTL) peptide (N50: S365–374, KCYGVSATKL), or
Th peptide (N60: S435–444, NYNYKYRYLR), at a final con-
centration of 1mg=mL (30). The plates were washed with
PBS, followed by incubation with biotinylated labeled anti-
mouse IFN-g, IL-2, and IL-4 mAbs at 1:1000 for 2 h at room
temperature. After additional washes, the wells were incu-
bated with streptavidin-conjugated HRP for 1 h at room
temperature, and developed with TMB substrate. Spots of
cytokine-producing T cells were counted by using an ELI-
SPOT reader and ImmunoSpot 3 software (Cellular Tech-
nology Ltd., Cleveland, OH). Results were expressed as the
number of spot-forming cells per 106 input cells.
Challenge of vaccinated mice with live SARS-CoV
Vaccinated mice were intranasally inoculated with SARS-
CoV strain GZ50 (5105 TCID50) as previously described
(16,17). The mice were sacrificed 5 d after virus challenge,
and the lungs were removed and stored at 808C for further
virological detection.
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
The viral RNA copies in the lung tissues were determined
by qRT-PCR according to a previously described protocol
(14). Briefly, total RNA was extracted from 20 mg of the lung
tissues using an RNeasy Mini kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. SARS-CoV
RNA was quantified in a 30-mL mixture containing 10mL
RNA, 15 mL 2TaqMan One-Step RT-PCR Master Mix
(Applied Biosystems, Foster City, CA), 0.75 mL 40
multiscribe, 0.25 mM each forward primer Af (Taq-772F 50-
AAG CCT CGC CAA AAA CGT AC-30), reverse primer Ar
(Taq-1000R 50-AAG TCA GCC ATG TTC CCG AA-30), and
probe (Taq-955T 50-FAM-TCA CGC ATT GGC ATG GAA
GTC ACA CT-TAMRA) (TIB Molbiol, Berlin, Germany),
using a fluorometric PCR instrument (ABI 7300; Applied
Biosystems).
Viral titer and total virus detection
The virus replication was detected by titration of the inoc-
ulated virus in lung tissues collected from sacrificed mice ac-
cording to a previously described protocol (14). Briefly, the
lung tissues were homogenized to a final concentration of
10% (w=v) suspension in DMEM. Tissue homogenates were
centrifuged, filtered, and inoculated into the monolayer of
Vero E6 cells seeded on 96-well tissue-culture plates. The re-
sults were evaluated after 3 d of culture under phase-contrast
microscopy, and viral titers using a CPE-based TCID50 test
were calculated by the Reed-Muench method. Viral titers
were expressed as log10TCID50=g of tissue, with a lowest de-
tection limit of 1.5 log10TCID50=g. The total amount of virus
was calculated by multiplying the weight of the lung tissues
and the viral titers measured in 10% of tissue homogenates.
Results
The expressed RBD219-CHO protein was correctly
folded and maintained intact conformation,
and was recognized by a majority of conformational
epitope-specific mAbs against RBD
The expressed RBD protein was analyzed for conforma-
tion by using mAbs targeting the conformational epitopes in
RBD. As shown in Fig. 2, the expressed protein reacted with
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5 of 6 selected mAbs recognizing conformational epitopes,
having the strongest reaction with the conformational V
mAb 33G4. It also reacted with mAb 17H9, that recognizes
the linear epitope in RBD. These results demonstrate that the
expressed RBD219-CHO protein is correctly folded and
maintains intact conformation.
RBD219-CHO induced high titers of RBD-specific
antibodies in vaccinated mice
In order to detect humoral immune responses induced by
RBD219-CHO protein, sera were collected from vaccinated
mice and analyzed with ELISA for RBD-specific antibodies.
As shown in Fig. 3A, all sera from 10 d after the first, second,
and third vaccinations showed strong antibody responses,
with those from the last vaccination demonstrating the
highest reactivity. The sera from pre-immunization (Pre),
and those from PBS controls had only background levels of
antibody responses. To determine the titer of RBD-specific
antibodies induced by RBD219-CHO protein, sera collected
10 d after the last vaccination were titrated at a series of
fourfold dilutions and A450 was measured. Fig. 3B indicates
that RBD219-CHO elicited high levels of RBD-specific anti-
bodies, with the end-point titer of 1:3.3106. In contrast, only
background levels of antibody were detected in the PBS
control group (Fig. 3B).
RBD219-CHO induced highly potent neutralizing
antibodies against in-vitro infection
by SARS pseudovirus and live SARS-CoV
Sera collected 10 d after the last vaccination were tested for
neutralizing activity against infection by SARS pseudovirus in
ACE2=293T cells, and live SARS-CoV in Vero E6 cells. As
shown in Fig. 4, 1:5.8104 4.9103 of NT50 were reached in
RBD219-CHO-vaccinated mouse sera to neutralize SARS
pseudovirus infection, levels higher than those of PBS controls.
High titers of RBD-specific IgG antibodies were also confirmed
to neutralize live SARS-CoV in infected Vero E6 cells, with
1:1.0103 2.4102 NT50 of neutralizing antibodies main-
tained in the vaccinated mice (Fig. 4). These results suggest
that highly potent neutralizing antibodies may be induced by
RBD219-CHO protein against both SARS pseudovirus and
live SARS-CoV infection in cell cultures in vitro.
RBD219-CHO was able to induce a relatively high level
of CTL and Th1-=Th-2 responses in vaccinated mice
For detection of the cellular immune responses potentially
induced by RBD219-CHO protein, mouse splenocytes were
collected 10 d after the last vaccination, and T-cell responses
were detected by ELISPOT. Splenocytes were stimulated
with N50 and N60 peptides specific to CD8þ T (CTL) cells
and CD4þ T (Th) cells, respectively, in the RBD of SARS-CoV
(30). For further detection of the cellular immune response,
purified RBD protein was also used for stimulation with a
final concentration of 1 mg=mL. As shown in Table 1,
RBD219-CHO induced RBD-specific CTL responses, with a
particularly high frequency of IL-2-producing CD8þ (CTL)
cells under the stimulation of the CTL peptide N50. Eva-
luation of Th-cell responses upon stimulation with the N60
peptide indicated that RBD219-CHO protein may elicit rel-
atively higher levels of Th-1 response, as represented by the
production of high numbers of IL-2-presenting T cells, in
addition to the induction of Th-2 response, which was indi-
cated by the presence of IL-4-secreting T cells in the spleens
of vaccinated mice. The results in Table 1 also show that the
cellular immune responses induced by RBD219-CHO protein
stimulation were generally higher than those elicited by the
CTL peptide N50 or Th peptide N60 stimulation alone,
probably because the recombinant protein covering the RBD
region contains much more CTL and=or Th epitopes. In
contrast, only a background level of cellular response was
detected in the splenocytes of mice from the PBS controls
(Table 1), or the cells stimulated with the supernatants of
CHO culture only (data not shown). These data suggest that
the expressed RBD219-CHO protein was able to induce a
relatively high level of cellular immune response in the
vaccinated mice.
Complete suppression of SARS-CoV replication
in lung tissues of virus-challenged mice, possibly
mediated by RBD219-CHO-induced
neutralizing antibody responses
To detect the protective immunity induced by RBD219-
CHO protein, vaccinated mice were challenged with SARS-
CoV GZ50, and mouse lung tissues were collected 5d post-virus
challenge to measure virus replication. The mice did not
FIG. 2. Western blot for detecting reactivity of RBD219-CHO protein with a panel of mAbs specific for distinct confor-
mational epitopes in RBD of SARS-CoV S protein. One mAb recognizing a linear epitope in RBD was also selected for
detection.
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develop obvious weight loss or clinical signs of disease in
both the control and vaccinated groups. No detectable rep-
lication was seen in all five mice vaccinated with RBD219-
CHO protein. In contrast, high levels of virus replication
were found in the lung tissues of PBS control mice (Fig. 5A).
The above results confirm that RBD219-CHO protein was
able to completely protect vaccinated mice from subsequent
SARS-CoV challenge.
To investigate the relationship between neutralizing anti-
body and virus protection, we compared the serum neu-
tralizing antibody titer and the viral RNA copies in the lung
tissues after the mice were challenged with live SARS-CoV
(GZ50). As shown in Fig. 5B, no detectable virus replication
was accompanied by high titers of neutralizing antibodies
(1:1.0103 2.4102) in the RBD219-CHO-vaccinated mice,
while high levels of virus replication (1:1.9103 4.1102
RNA copies=mg of lung tissue) and undetectable levels of
serum neutralizing antibodies (<1:20) were found in the PBS
control mice. These results suggest that neutralizing anti-
body responses may play a critical role in the inhibition of
SARS-CoV replication.
Discussion
Vaccines based on the recombinant S protein of SARS-CoV
have been shown to induce humoral immune responses,
especially neutralizing antibodies against SARS-CoV (23,33,
35,60). High titers of cross-neutralizing antibodies against
FIG. 3. Detection of RBD-specific antibodies in sera of mice immunized with RBD219-CHO protein and PBS controls. The
data are presented as mean A450 standard error (SE) from five mice per group. (a) IgG antibody detected in sera (at 1:3000
dilution) collected before immunization (Pre) and 10 d after each vaccination are shown here. (b) RBD-specific antibody titer
detected in sera collected 10 d after the last vaccination are shown here.
FIG. 4. Detection of neutralizing antibodies in sera of mice vaccinated with RBD219-CHO or PBS controls. Sera collected
10 d after the last immunization were tested for neutralizing activity against infection by SARS pseudovirus in ACE2=293T
cells, and live SARS-CoV in Vero E6 cells. The data are presented as mean NT50 SE of five mice per group.
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pseudovirus in vitro were detected in rRBD-vaccinated mice
and rabbits (24). Protective humoral responses were detected
in protein-vaccinated rabbits, with antisera against S contain-
ing neutralizing antibodies for SARS-CoV infection in vivo
(43). These reports demonstrated that S protein-induced neu-
tralizing antibodies play important roles in fighting SARS-
CoV infection.
We previously reported that a recombinant protein con-
taining a 193-aa RBD with Fc tag (RBD193-Fc) induced
highly potent neutralizing antibody responses and protective
immunity in vaccinated animals (14). In order to eliminate
any potential adverse effects that might be induced by
RBD193-Fc when used as a vaccine component in humans,
we have expressed several RBD proteins with the Fc tag
removed in mammalian cells 293T (RBD-293T) and CHO-K1
(RBD193-CHO), insect cells Sf9 (RBD-Sf9),. and E. coli (RBD-
Ec). Unlike RBD proteins expressed in 293T, Sf9, and E. coli,
that may induce complete protection against live SARS-CoV
challenge in vaccinated mice, the 193-aa RBD protein ex-
pressed in CHO-K1 cells (RBD193-CHO) protected a major-
ity of the mice from virus challenge, with virus replication
detected in two of five mice (13,15). When we expressed a
219-mer RBD protein in the same cell line of CHO-K1
(RBD219-CHO), the newly-designed protein elicited high ti-
ters of RBD-specific antibodies with potent neutralizing ac-
tivity against both SARS pseudovirus and live SARS-CoV
infection in cell cultures in vitro. Like rRBD proteins ex-
pressed in 293T, Sf9, and E. coli cells, RBD219-CHO was able
to protect all vaccinated mice against SARS-CoV challenge
in vivo (Fig. 5). Similarly to other rRBD proteins expressed
above, this mammalian cell CHO-K1-expressed RBD protein
without the Fc fusion tag reacted with the majority of the
mAbs specific for the conformational and linear epitopes in
RBD, suggesting that it maintains intact conformation and
proper antigenicity (Fig. 2). Similarly to RBD193-CHO pro-
tein, a stable cell line could be established in the CHO-K1 cell
lines for long-term expression of the RBD219-CHO protein
(data not shown). The RBD219-CHO protein (residues 318–
536) was expressed with an extension of 26 residues at the C
terminus of the RBD193-CHO protein (residues 318–510).
This extended fragment may assist RBD to refold into a more
stable or more immunogenic conformation to induce more
potent protective immunity in the vaccinated animals. Fu-
ture comparison of the structure and immune responses and
long-term protection of these two proteins is warranted.
In addition to humoral immune responses, cellular im-
mune responses may play a role in the clearance of SARS-
CoV infection, in which both CD4þ and CD8þ T cells are
involved in the immune response against virus infection.
Memory T-cell responses against S protein were shown to
continue for more than 1 y after SARS-CoV infection, as in-
dicated by the production of IFN-g (54). An increased specific
Table 1. ELISPOT Detection of Cellular Immune Responses in RBD219-CHO-Vaccinated Micea
RBD219-CHO (SFC=106 cells) PBS (SFC=106 cells)
Stimulus IFN-g IL-2 IL-4 IFN-g IL-2 IL-4
CTL peptide N50 63 21 298 100 163 89 7 3 4 1 4 0
Th peptide N60 143 66 645 232 905 196 8 1 3 0 3 0
RBD219-CHO protein 465 66 1044 278 833 273 5 0 5 1 5 1
aCytokine-producing cells were detected by ELISPOT under the stimulation of N50 and N60 peptides containing SARS-CoV RBD-specific
CD8þ T-cell and CD4þ T-cell epitopes, respectively, and RBD219-CHO protein. PBS was used as the control. The data are expressed as
mean SE of cytokine spot-forming cells (SFC)=106 cells of five mice per group.
FIG. 5. Detection of protective immunity in mice immunized with RBD219-CHO protein or PBS controls. Mice vaccinated
with RBD219-CHO protein were challenged with live SARS-CoV (GZ50). (a) SARS-CoV replication in the lung tissues of
challenged mice was detected and expressed as log10TCID50=g of tissue. The detection limit was 1.5 log10TCID50=g of lung
tissue. M1–M5 indicate the five mice used per group. (b) The number of SARS-CoV RNA copies in the lung tissues of mice
challenged with live SARS-CoV GZ50 were measured by qRT-PCR, and expressed as RNA copies=mg of lung tissue. The
neutralizing antibody titers (NT50) in the sera of the mice are also shown. The data are presented as mean SE of five mice
per group. The experiment was performed three times and similar results were obtained.
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CTL response was induced by an S2 fragment encoding
residues 681–980 (22). Immunization of mice with a DNA
fragment encoding the S protein was demonstrated to induce
both CD4þ and CD8þ T-cell responses (31). In a Phase I
human study, an S protein-expressing DNA vaccine elicited
SARS-CoV-specific CD4þ T-cell responses in all tested heal-
thy adults, and CD8þ T-cell responses in 20% of individuals
(42). Both CTL and Th-1=Th-2 responses were detected in
this study in RBD219-CHO-vaccinated mouse splenocytes,
more evidence of the high immunogenicity and antigenicity
of the expressed RBD protein when used as a vaccine can-
didate (Table 1).
Although both humoral and cellular immune responses
are important for suppression of SARS-CoV infection, neu-
tralizing antibodies may be the key factor for protecting mice
from subsequent virus challenge (13,14,50). Long-term protec-
tion mediated by neutralizing antibodies could be achieved by
immunization of mice with a single dose of an attenuated
vesicular stomatitis virus (VSV) recombinant bearing S pro-
tein (VSV-S) (34). A recombinant secreted protein containing
14–762 residues of the S protein could provide sufficient
neutralizing antibodies to protect against SARS-CoV infec-
tion (2). The protective immunity seen in the mice vaccinated
with an S protein-expressing DNA vaccine was mediated by
humoral immunity rather than by a T-cell-dependent im-
mune mechanism (55). In agreement with the above reports,
our results show that neutralizing antibodies induced by
RBD219-CHO protein play a significant role in the suppres-
sion of SARS-CoV infection (Fig. 5).
We and others have demonstrated that RBD of SARS-CoV
S protein is the basis for the development of vaccines against
SARS-CoV (6,11,16,17,26,32). High titers of neutralizing an-
tibodies and protective immunity could be induced by sub-
unit vaccines based on the RBD protein with or without
fusion segments (14,56). However, RBD-based vaccines
without the fusion tag would eliminate any potential adverse
effects induced by fusion proteins when used in humans
(13). In agreement with our previous reports, the results of
this study further confirm that the recombinant RBD protein
without the Fc fusion fragment is able to induce potent neu-
tralizing antibody responses and protection against infection
by SARS-CoV, suggesting the possibility of the development
of RBD subunit-based vaccines for SARS prevention.
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